31 May 2023

South Africa is one of five countries involved in a phase three trial to develop a first-in- class antibiotic for gonorrhoea – one of the three most common sexually transmitted infections in the world, which has serious consequences if left untreated but which has limited treatment options due to antimicrobial resistance.

Gonorrhoea is rising rapidly across around the globe, with 82m new cases estimated annually, and in South Africa, 2m new infections every year, so the new trial offers much cause for optimism, notes MedicalBrief.

The Global Antibiotic Research & Development Partnership (GARD P) and Innoviva Specialty Therapeutics, a subsidiary of Innoviva, last week announced the completion of recruitment for their global phase three pivotal registration trial of oral zoliflodacin, an investigational antibiotic being developed to treat uncomplicated gonorrhoea.

Read the article